- Home
- BGMS vs OSRHW Comparison
BGMS vs OSRHW Comparison
Compare BGMS & OSRHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | BGMS | OSRHW |
|---|---|---|
| Founded | 1996 | N/A |
| Country | Malaysia | United States |
| Employees | N/A | 21 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | N/A |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | BGMS | OSRHW |
|---|---|---|
| Price | $0.93 | $0.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 147.8K | 25.0K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $137.21 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.74 | $0.03 |
| 52 Week High | $6.70 | $0.08 |
Technical Indicators
Market Signals| Indicator | BGMS | OSRHW |
|---|---|---|
| Relative Strength Index (RSI) | 38.41 | 48.91 |
| Support Level | $0.74 | $0.04 |
| Resistance Level | $1.12 | $0.07 |
| Average True Range (ATR) | 0.06 | 0.00 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 13.95 | 40.00 |
Price Performance
Historical ComparisonAbout BGMS Bio Green Med Solution Inc.
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.
About OSRHW OSR Holdings Inc. Warrant
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.